FGF21 and obesity disorder: Long-acting FGF21 analogs and agonists that mimic FGF21 action are under investigation in clinical trials in patients with obesity and diabetes (ClinicalTrials registration no. NCT02413372, NCT02538874, NCT2593331, NCT02708576, and NCT03060538).